Vaxcyte, Inc. (PCVX) stock forecast & analysis
73.82
NasdaqGS · USD
Up: +17.34, +30.7%
1 analysis
- Open
- 87.21
- Previous close
- 56.48
- Day range
- 71.60 – 90.75
- 52-week range
- 39.87 – 90.75
- Volume (shares)
- 14.84M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 148.81M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 1.23
- Market cap
- 10.98B
Market Scanner’s AI analysis of Vaxcyte, Inc. (PCVX), updated October 2026: Vaxcyte's PCVX stock surges on positive Phase 3 pneumococcal vaccine data, overshadowing consistent net losses.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Vaxcyte, Inc. (PCVX) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Vaxcyte's PCVX stock surges on positive Phase 3 pneumococcal vaccine data, overshadowing consistent net losses.
Recent analyses for Vaxcyte (PCVX) covered significant positive topline data from its Phase 3 trial for VAX-31, a pneumococcal conjugate vaccine candidate, which met primary endpoints and led to a substantial stock price increase. This development has been favorably compared to competitors and is seen as validating broad coverage. The analyses also noted the company's consistent net losses and increasing annual losses from 2022 to 2025, alongside a strong upward momentum in stock price with the RSI indicating overbought territory.
PCVX news & sentiment
News reports highlighted a significant surge in Vaxcyte's stock following positive Phase 3 trial data for its vaccine candidate, VAX-31, with the news overshadowing general sector updates. Social media discussions were not covered in the provided notes.
PCVX technical picture
PCVX stock exhibited strong upward momentum, trading significantly above both its 50-day and 200-day SMAs, with the shorter-term average above the longer-term one. Momentum indicators like the RSI were elevated, suggesting overbought conditions, while the MACD showed positive momentum.
Fundamentals
The company has consistently reported net losses, with operating and net losses increasing annually from 2022 to 2025 and continuing in the most recent reported quarter. Despite these losses, the company holds substantial shareholder equity and total assets exceeding total liabilities.
Factors discussed — upside
- Positive topline data from Phase 3 trial for VAX-31 met primary endpoints
- Stock price surge of 50% to a new 52-week high
- Strong upward momentum with price significantly above 50-day and 200-day SMAs
- 50-day SMA trading above 200-day SMA indicating bullish long-term trend
- VAX-31 positioned to validate broad coverage
Factors discussed — risks
- Consistent net losses reported
- Increasing net losses on an annual basis from 2022 to 2025
- RSI at 79.69 indicating overbought territory
- Vaccine trial data
- Stock momentum
- Financial performance
- Biotechnology industry
Summary updated .
PCVX technical indicators
Common technical indicators for PCVX, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 58.92 | Price above |
| 10-day exponential moving average | 60.23 | Price above |
| Relative strength index (14-day) | 76.59 | Overbought |
| MACD line (12/26/9) | 0.5844 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 51.67 – 66.33 | Price above the upper band |
Analyses
Recent PCVX.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Vaxcyte, Inc.?
- The bull case centers on VAX-31's successful Phase 3 trial, which met its primary endpoints and has been favorably compared to competitors, positioning it to validate broad coverage. This positive data has driven a significant stock price surge to a 52-week high, supported by strong upward momentum and a bullish long-term trend indicated by moving averages.
- What are the risks for Vaxcyte, Inc.?
- Risks for the company include a history of consistent net losses, with annual losses increasing from 2022 to 2025. Additionally, the stock's recent surge has pushed its Relative Strength Index into overbought territory, suggesting potential for a reversal.
- Is Vaxcyte, Inc. bullish or bearish?
- Recent AI analyses of Vaxcyte, Inc. examined factors on both sides. Discussed upside: The bull case centers on VAX-31's successful Phase 3 trial, which met its primary endpoints and has been favorably compared to competitors, positioning it to validate broad coverage. This positive data has driven a significant stock price surge to a 52-week high, supported by strong upward momentum and a bullish long-term trend indicated by moving averages. Discussed risks: Risks for the company include a history of consistent net losses, with annual losses increasing from 2022 to 2025. Additionally, the stock's recent surge has pushed its Relative Strength Index into overbought territory, suggesting potential for a reversal. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Vaxcyte, Inc.?
- News reports highlighted a significant surge in Vaxcyte's stock following positive Phase 3 trial data for its vaccine candidate, VAX-31, with the news overshadowing general sector updates. Social media discussions were not covered in the provided notes.
- How does Market Scanner analyse Vaxcyte, Inc.?
- Every analysis of Vaxcyte, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh PCVX.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.